Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503848
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers MAMBO Phase I
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers The MAMBO Study Phase I
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAMBO
Brief Summary:
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan
Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks
Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks
Detailed Description:
There is still an unmet need in acute migraine treatment some patients dont respond properly to acute medication
There are some interindividual differences in clinical characteristics of migraine attacks These differences may determine the response to acute treatment Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment
The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan
Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan
There are some interindividual differences in clinical characteristics of migraine attacks These differences may determine the response to acute treatment Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment
The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan
Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None